Cartesian Therapeutics Q1 FY26 net loss widens to $39.2 million

• Cartesian Therapeutics posted a net loss of USD 39.2 million, more than doubling from year-ago levels.
• Revenue fell 92.91% to USD 78,000.
• Operating loss widened 21.05% to USD 26.5 million.
• Research and development expense climbed 32.56% to USD 19.5 million, driven by higher costs for Phase 3 AURORA in myasthenia gravis.
• Enrollment progressed in Phase 3 AURORA for Descartes-08 in MG, while Phase 2 TRITON in dermatomyositis and antisynthetase syndrome was initiated and multiple patients enrolled in Phase 1/2 HELIOS in juvenile dermatomyositis.
• Cash, cash equivalents and restricted cash totaled USD 120.4 million at March 31, 2026, expected to fund operations into mid-2027 including completion of Phase 3 AURORA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cartesian Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604300700PRIMZONEFULLFEED9710011) on April 30, 2026, and is solely responsible for the information contained therein.